INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer

BACKGROUND: Triple negative breast cancer (TNBC) accounts for 10-20% of breast cancers but has no specific therapy. While TNBC may be more sensitive to chemotherapy than other types of breast cancer, it has a poor prognosis. Most TNBC relapses occur during the five years following treatment, however...

Descripción completa

Detalles Bibliográficos
Autores principales: Veyssière, Hugo, Lusho, Sejdi, Molnar, Ioana, Kossai, Myriam, Bernadach, Maureen, Abrial, Catherine, Bidet, Yannick, Radosevic-Robin, Nina, Durando, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268015/
https://www.ncbi.nlm.nih.gov/pubmed/34249690
http://dx.doi.org/10.3389/fonc.2021.653370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268015/
https://www.ncbi.nlm.nih.gov/pubmed/34249690
http://dx.doi.org/10.3389/fonc.2021.653370

Ejemplares similares